Bcma car-t cells for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment where your own immune cells (T cells) are collected, modified to find and attack myeloma cells, and given back to you. It is for people with multiple myeloma that has come back or not responded to several standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have multiple myeloma that has not responded to or has returned after at least three different treatments, including a proteasome inhibitor and an immunomodulatory drug.
- Your disease must show signs of being measurable (like certain protein levels in blood or urine).
- You should be able to take care of yourself (performance status 0-1) and have a life expectancy of at least 3 months.
- Your blood counts and organ functions (heart, lungs, kidneys, liver) must be within safe limits.
- You cannot have had CAR-T therapy or BCMA-targeted treatment before, and you cannot have certain infections or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with multiple myeloma that has come back or not responded to several prior treatments. It aims to see if this therapy can help control the disease.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and destroy myeloma cells that have a protein called BCMA. It is for people whose multiple myeloma has come back or hasn't responded to other treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to fight multiple myeloma that has returned or not responded to earlier treatments. The treatment is designed to target and kill myeloma cells more effectively.
Hear when a new Relapsed/Refractory Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.